CPT-11 Synthesis via Pyridine Mediator and Crystallization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy-camptothecin hydrochloride trihydrate, known as CPT-11, face low yield and instability of intermediates, leading to impurities and inefficiencies in bulk production, with a need for an environmentally friendly and economically viable process that ensures high purity.
Innovation Solution
A process involving the coupling of [1,4']-bipiperidinyl-1'-carbonyl chloride with 7-hydroxy camptothecin in the presence of acetamide and suitable solvents, followed by crystallization, which stabilizes the intermediate and increases yield, allowing for the production of pure CPT-11 with minimal impurities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional methods are used to produce CPT-11, then the production process is established, but the yield is low and impurities are generated
Solution Approach 1:
The patent changes the chemical reaction parameters by using a different condensation approach - reacting 7-ethyl-10-hydroxycamptothecin with 1-chlorocarbonyl-4-piperidinopiperidine in the presence of pyridine at room temperature, rather than using conventional high-temperature or multi-step methods. This parameter change achieves both high yield (95% or higher) and high purity (99.9% or higher) simultaneously
Solution Approach 2:
The patent uses pyridine as an intermediary substance to facilitate the condensation reaction between 7-ethyl-10-hydroxycamptothecin and 1-chlorocarbonyl-4-piperidinopiperidine. Pyridine acts as a catalyst and solvent that enables the reaction to proceed efficiently at room temperature, producing high-yield intermediate that can be directly converted to final product without additional purification steps
2Productivity
If intermediates are stabilized to increase yield, then production efficiency improves, but process complexity may increase
Solution Approach 1:
The patent performs preliminary stabilization of the intermediate compound by conducting the condensation reaction under controlled conditions (room temperature, pyridine presence) that inherently stabilize the intermediate 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin. This preliminary action ensures high yield (95% or higher) and eliminates the need for additional stabilization steps or complex equipment, maintaining process simplicity while achieving excellent results
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This process results in a stable and high-yield production of CPT-11 with purity exceeding 99.9% as measured by HPLC, reducing impurities and operational challenges, and aligning with regulatory standards for pharmaceutical-grade purity.
Implementation Method 1
condensation of 7-ethyl-10-hydroxy camptothecin with 1-chlorocarbonyl-4-piperidinopiperidine in presence of pyridine at room temperature
Implementation Method 2
concentrated and isolated to afford the intermediate
Implementation Method 3
dissolved in water and treated with HCl
Implementation Method 4
7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy-camptothecin
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to process for the preparation of 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy-camptothecin hydrochloride trihydrate and process for the isolation of 1-chlorocarbonyl-4-piperidinopiperidine and novel crystalline form of 1-chlorocarbonyl-4-piperidinopiperidine and 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy-camptothecin.